Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

Daniel James McGrail; P. G. Pilié; N. U. Rashid; L. Voorwerk; M. Slagter; M. Kok; E. Jonasch; M. Khasraw; Amy B Heimberger; Naoto T Ueno; R. Ferrarotto; J. T. Chang; S. Y. Lin

doi:10.1016/j.annonc.2021.06.017

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

Daniel James McGrail, P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, Amy B Heimberger, Naoto T Ueno, R. Ferrarotto, J. T. Chang, S. Y. Lin

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	1194-1197
Number of pages	4
Journal	Annals of Oncology
Volume	32
Issue number	9
DOIs	https://doi.org/10.1016/j.annonc.2021.06.017
State	Published - Sep 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2021.06.017

Cite this

McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Ueno, N. T., Ferrarotto, R., Chang, J. T., & Lin, S. Y. (2021). Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al. Annals of Oncology, 32(9), 1194-1197. https://doi.org/10.1016/j.annonc.2021.06.017

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al. / McGrail, Daniel James; Pilié, P. G.; Rashid, N. U. et al.
In: Annals of Oncology, Vol. 32, No. 9, 09.2021, p. 1194-1197.

Research output: Contribution to journal › Letter › peer-review

McGrail, DJ, Pilié, PG, Rashid, NU, Voorwerk, L, Slagter, M, Kok, M, Jonasch, E, Khasraw, M, Heimberger, AB, Ueno, NT, Ferrarotto, R, Chang, JT & Lin, SY 2021, 'Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.', Annals of Oncology, vol. 32, no. 9, pp. 1194-1197. https://doi.org/10.1016/j.annonc.2021.06.017

@article{a1ee6841c9cd4cf3b5c29bef99514c56,

title = "Reply to: {\textquoteleft}Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.{\textquoteright} by D. Fabrizio et al.",

author = "McGrail, {Daniel James} and Pili{\'e}, {P. G.} and Rashid, {N. U.} and L. Voorwerk and M. Slagter and M. Kok and E. Jonasch and M. Khasraw and Heimberger, {Amy B} and Ueno, {Naoto T} and R. Ferrarotto and Chang, {J. T.} and Lin, {S. Y.}",

note = "Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689] and Susan G. Komen [grant number PDF17483544] to DJM. MKh has served as a consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche and Jackson Laboratory for Genomic Medicine and received research funding from AbbVie, Bristol Myers Squibb (BMS) and Specialized Therapeutics. ABH has stock options and is an advisory board member of Caris Life Sciences, serves on the advisory board of WCG Oncology, has received licensing fees from Celldex Therapeutics and DNAtrix and received research funding from Merck. MKo has advisory roles for BMS, Roche, Merck Sharp & Dohme (MSD) and Daiichi Sankyo, and the institute receives research funding from AstraZeneca, BMS and Roche outside the submitted work. DJM, PGP, EJ and SYL have a pending patent on a gene expression signature to predict response to immune checkpoint blockade. All other authors have declared no conflicts of interest. Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689 ] and Susan G. Komen [grant number PDF17483544 ] to DJM. ",

year = "2021",

month = sep,

doi = "10.1016/j.annonc.2021.06.017",

language = "English (US)",

volume = "32",

pages = "1194--1197",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "9",

}

TY - JOUR

T1 - Reply to

T2 - ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

AU - McGrail, Daniel James

AU - Pilié, P. G.

AU - Rashid, N. U.

AU - Voorwerk, L.

AU - Slagter, M.

AU - Kok, M.

AU - Jonasch, E.

AU - Khasraw, M.

AU - Heimberger, Amy B

AU - Ueno, Naoto T

AU - Ferrarotto, R.

AU - Chang, J. T.

AU - Lin, S. Y.

N1 - Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689] and Susan G. Komen [grant number PDF17483544] to DJM. MKh has served as a consultant or advisory roles for Janssen, AbbVie, Ipsen, Pfizer, Roche and Jackson Laboratory for Genomic Medicine and received research funding from AbbVie, Bristol Myers Squibb (BMS) and Specialized Therapeutics. ABH has stock options and is an advisory board member of Caris Life Sciences, serves on the advisory board of WCG Oncology, has received licensing fees from Celldex Therapeutics and DNAtrix and received research funding from Merck. MKo has advisory roles for BMS, Roche, Merck Sharp & Dohme (MSD) and Daiichi Sankyo, and the institute receives research funding from AstraZeneca, BMS and Roche outside the submitted work. DJM, PGP, EJ and SYL have a pending patent on a gene expression signature to predict response to immune checkpoint blockade. All other authors have declared no conflicts of interest. Funding Information: This work was supported by the National Cancer Institute at the National Institutes of Health [grant number K99CA240689 ] and Susan G. Komen [grant number PDF17483544 ] to DJM.

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85111069439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111069439&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.06.017

DO - 10.1016/j.annonc.2021.06.017

M3 - Letter

C2 - 34166757

AN - SCOPUS:85111069439

SN - 0923-7534

VL - 32

SP - 1194

EP - 1197

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9

ER -

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this